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Trafficking of leukocytes in immune surveillance and
inflammatory responses is activated by chemokines
engaging their receptors. Sulfation of tyrosine resi-
dues in peptides derived from the eosinophil chemo-
kine receptor CCR3 dramatically enhances binding
to cognate chemokines. We report the structural ba-
sis of this recognition and affinity enhancement. We
describe the structure of a CC chemokine (CCL11/
eotaxin-1) bound to a fragment of a chemokine re-
ceptor: residues 8–23 of CCR3, including two sulfo-
tyrosine residues. We also show that intact CCR3 is
sulfated and sulfation enhances receptor activity.
The CCR3 sulfotyrosine residues form hydrophobic,
salt bridge and cation-p interactions with residues
that are highly conserved in CC chemokines. How-
ever, the orientation of the chemokine relative to
the receptor N terminus differs substantially from
those observed for two CXC chemokines, suggest-
ing that initial binding of the receptor sulfotyrosine
residues guides subsequent steps in receptor activa-
tion, thereby influencing the receptor conformational
changes and signaling.
INTRODUCTION
A critical component of inflammatory responses is the traf-
ficking of leukocytes to infected or injured tissues. The selectivity
of leukocyte recruitment is regulated by the interactions of
secreted proinflammatory chemokines with chemokine recep-
tors, a family of G protein-coupled receptors expressed in leuko-
cyte cell membranes (Lau et al., 2004; Thelen and Stein, 2008).
Similar interactions occur between homeostatic chemokines
and their receptors to regulate leukocyte homing to lymph nodes
during normal immune surveillance (Moser et al., 2004).
Chemokines and their receptors have coevolved into two ma-
jor families, designated CC and CXC based on the arrangementStructure 22, 1571–15of cysteine residues near the N termini of the chemokines. CC
and CXC chemokines have similar protomer structures but
form distinct quaternary structures so that monomeric or dimeric
CXC chemokines can activate CXC receptors, whereas only
monomeric CC chemokines can activate CC receptors (Jin
et al., 2007; Nasser et al., 2009; Tan et al., 2012; Veldkamp
et al., 2008). Mutational studies have established the ‘‘two-
site’’ model, in which chemokines of both families use the resi-
dues following the CC/CXC motif (the ‘‘N-loop’’ region) for initial
binding of the N-terminal regions of their receptors and use res-
idues preceding the CC/CXC motif (the chemokine ‘‘N-terminal’’
region) for subsequent receptor activation (Crump et al., 1997).
Tyrosines adjacent to acidic residues in the N termini of most
chemokine receptors are posttranslationally modified by sulfa-
tion (Stone et al., 2009). Tyrosine sulfation increases the binding
affinities of chemokine ligands and canmodify the selectivity of a
receptor among a group of potential ligands (Choe et al., 2005;
Ludeman and Stone, 2014; Zhu et al., 2011). Thus, differential
sulfation of chemokine receptors is a possible mechanism for
regulation of cellular responses to chemokines.
Due to their central roles in inflammatory diseases, chemo-
kine:receptor interactions are the targets of numerous drug
discovery efforts (Horuk, 2009; Mysinger et al., 2012; Viola and
Luster, 2008). Development of anti-inflammatory or immune reg-
ulatory agents that block specific chemokine:receptor interac-
tions would benefit greatly from a structural understanding of
these interactions. Currently, the only reported structures of che-
mokine receptors are thoseofCXCR4bound to small-molecule or
peptide inhibitors (Wuet al., 2010), unligandedCXCR1 (Park et al.,
2012), and CCR5 bound to the HIV drug maraviroc (Tan et al.,
2013b). Structuresof twodimericCXCchemokines,CXCL8/inter-
leukin-8 (IL-8) and CXCL12/SDF-1, bound to N-terminal frag-
ments of their respective receptors, have revealed details of the
recognition between the receptor N termini and the N-loop re-
gions of CXC chemokines (Skelton et al., 1999; Veldkamp et al.,
2008). Considering that CXC chemokine dimers and their mono-
mers have distinct activities (Nasser et al., 2009; Veldkamp
et al., 2008), it remains to be determinedwhether these structures
are representative of theactivemonomer interactions. Todate, no
structures have been reported for any CC chemokines or any
monomeric chemokines bound to receptor fragments.81, November 4, 2014 ª2014 Elsevier Ltd All rights reserved 1571
Figure 1. Sulfation Enhances Activation of CCR3
ERK1/2 phosphorylation in response to CCR3 activation by CCL11 was
monitored in untreated cells and cells grown in the presence of 30 mM sodium
chlorate to inhibit tyrosine sulfation. Inset: Treatment with 30 mM sodium
chlorate did not affect ERK1/2 phosphorylation induced by the positive control
(10% FBS). Data shown represent mean ± SEM of at least three independent
experiments.
Structure
Receptor Sulfopeptide Bound to CC ChemokineHerein we report the solution structure of the monomeric CC
chemokine CCL11/eotaxin-1 bound to a tyrosine-sulfated frag-
ment of the CC chemokine receptor CCR3. CCR3 is expressed
on eosinophils, basophils, and Th2 cells, and activation
of CCR3 by CCL11 and related chemokines stimulates recruit-
ment of these leukocytes in allergic asthma, atopic dermatitis,
and parasitic infections (Jose et al., 1994a, 1994b; Rankin
et al., 2000; Yawalkar et al., 1999). Sulfation of both Tyr-16 and
Tyr-17 within N-terminal peptides from CCR3 enhances CCL11
affinity 100-fold and also enhances selectivity among several
CC chemokine ligands (Simpson et al., 2009; Zhu et al., 2011).
The structure reveals residues critical for sulfotyrosine (Tys)
recognition and highlights the potential influence of initial binding
interactions on receptor activation.
RESULTS
Sulfation Enhances CCR3 Activity
The N-terminal extracellular region of CCR3 (residues 1–35) con-
tains two adjacent tyrosine residues (Tyr-16 and Tyr-17). Based
on their proximity to two aspartic acid residues (sequence
YYDD), the two tyrosine residues are predicted to be sulfated
(Liu et al., 2008), and sulfation of the CCR3 N-terminal region oc-
curs when this region is fused to an immunoglobulin domain and
expressed in HeLa cells (Farzan et al., 1999). To determine the
influence of CCR3 sulfation on chemokine activation, we moni-
tored the activity of CCR3 expressed in human embryonic kidney
(HEK293) cells grown in the presence and absence of the sulfa-
tion inhibitor sodium chlorate (30mM). Chlorate treatment signif-
icantly reduced the potency and maximum response of CCL11
on CCR3, as measured by phosphorylation of ERK1/2 (Figure 1);
pEC50 values are 9.6 ± 0.3 for untreated and 7.0 ± 0.3 for chlo-
rate-treated cells (p = 0.003). Chlorate treatment did not affect
ERK1/2 phosphorylation in response to FBS (Figure 1, inset),
indicating that ERK signaling is not globally disrupted by chlo-1572 Structure 22, 1571–1581, November 4, 2014 ª2014 Elsevier Ltdrate. These experiments show that CCR3 is sulfated and sulfa-
tion enhances receptor activity.
NMR Sample Conditions
We used multidimensional nuclear magnetic resonance
(NMR) spectroscopy to monitor the interaction of recombi-
nant, isotope-enriched CCL11 with a synthetic sulfopeptide,
Su1617, spanning residues 8–23 of CCR3, including the two sul-
fotyrosine residues of CCR3 (designated Tys-216 and Tys-217;
peptide residues are numbered 208–223 to avoid ambiguity).
Upon titration of CCL11 with Su1617 at 25C in 20 mM deuter-
ated sodium acetate, 0.02% NaN3, 5% D2O (pH 6.5), many
NMR spectral signals shifted gradually from free to bound posi-
tions, indicating that the exchange rate between free and bound
components was fast in comparison with the frequency changes
of these signals. However, a subset of peaks broadened signifi-
cantly over the course of the titration and intermolecular nuclear
Overhauser enhancements (NOEs) were weak at or below 25C,
indicative of intermediate exchange and consistent with the
equilibrium dissociation constant (Kd) of approximately 1 mM at
25C (Simpson et al., 2009; Zhu et al., 2011). Nonetheless, at
40C, the intermolecular NOEs were substantially stronger, pre-
sumably due to a combination of faster exchange rates and
a shorter rotational correlational time leading to a reduction in
line width. The structure of CCL11:Su1617 was determined
from multidimensional NMR data acquired at 40C. Samples
with concentrations in the range 200–400 mM containing
CCL11 and Su1617 at a 1:1 molar ratio in 20 mM deuterated so-
dium acetate, 0.02%NaN3, and 5%D2O (pH 6.5) were prepared
by NMR-monitored titration until saturation was achieved and
used for structure determination.
NMR Assignments
At the temperature required for observation of intermolecular
NOEs, resonances from the ordered regions of CCL11 were
readily assignable by standard triple resonance NMR methods
(Sattler et al., 1999). However, for more flexible regions, back-
bone amide resonances were not uniformly observable and
several proline resonances hindered standard sequential assign-
ments. Nevertheless, a substantial proportion of the residues in
these regions could be assigned using 3D HCAN and (HB)
CBCA(CO)N(CA)HA experiments, which do not rely on observa-
tion of amide 1H resonances (Kanelis et al., 2000). Similarly,
direct sequential assignment of peptide resonances was difficult
becausemost peptide amide resonanceswere not observable at
40C. Therefore, observable peptide resonances were assigned
indirectly by: (1) analysis of TOCSY and ROESY spectra of the
free peptide at 25C; (2) monitoring peptide resonance move-
ments from 25C to 40C; and (3) monitoring peptide resonance
movements upon addition of isotope-enriched protein at 40C
(Figure S1 available online).
Structure Determination
The structure of the CCL11:Su1617 complex was determined
using the geometric restraints summarized in Table 1. Most
importantly, 55 intermolecular NOEs were observed, 47 of which
involved resonances of the two peptide Tys residues, five
involved the other peptide aromatic residue (Phe-211), and the
remaining three involved Leu-223. Figures 2A and 2B showAll rights reserved
Table 1. Input Restraints for Structure Calculation
Intraprotein Restraints
Distance Restraints
Intraresidue (i  j = 0) 260
Sequential (ji  jj = 1) 239
Short range (ji  jj% 4) 168
Long range (ji  jj > 4) 362
Total 1,029
Dihedral Restraints
F 29
J 29
Total 58
Hydrogen Bond Restraints 22
Total intraprotein restraints 1,109
Total intraprotein restraints per residue 15.0
Total intraprotein restraints per ordered residue
(12–29, 37–68)
22.2
Intrapeptide Distance Restraints
Intraresidue (i  j = 0) 16
Sequential (ji  jj = 1) 16
Short range (ji  jj% 4) 13
Long range (ji  jj > 4) 6
Total 51
Total intrapeptide restraints per peptide residue (211–223) 3.9
Total intrapeptide restraints per peptide residue (216–223) 6.4
Intermolecular Distance Restraints 55
Total intermolecular restraints per peptide residue (211–223) 4.2
Total intermolecular restraints per peptide residue (216–223) 6.9
Structure
Receptor Sulfopeptide Bound to CC Chemokineplanes corresponding to Tys aromatic and Phe-211 Hd reso-
nances in the F3-filtered 13C-HSQC-NOESY spectrum. Peaks
observed on these planes correspond to CH groups in the pro-
tein that make NOE contacts with the relevant peptide protons.
The specific NOEs observed between peptide and protein resi-
dues are represented schematically in Figure 2C. These NOEs
clearly define the position and orientation of Su1617 between
the N-loop/310-turn and the b2-b3 hairpin structural elements
of CCL11, consistent with the chemical shift changes observed
upon binding (Simpson et al., 2009; Zhu et al., 2011).
In addition to the intermolecular NOEs, the bound peptide
structure was restrained by 19 NOEs between nonsequential
peptide side chains in the C-terminal half of the peptide (Ser-
215 to Leu-223). These included 13 NOEs between side chains
of residues separated by three residues and six NOEs between
residues 5 or 6 apart in the sequence (Figure 2D). Although intra-
peptide hydrogen bonds were not included in the structural re-
straints, the calculated structures consistently indicated the
presence of hydrogen bonds from Val-220 HN to Tys-217 O
and from Leu-223 HN to Val-220 O.
The atomic coordinates for the final ensemble of 20 structures,
chemical shifts, and structural constraints have been deposited
in the Protein Data Bank (PDB accession code 2MPM) and Bio-
MagResBank (BMRB accession code 19989). Statistics for the
final ensemble of 20 structures are summarized in Table 2 and
the structure is shown in Figure 3A. Chemokine residues 1–11,Structure 22, 1571–1530–36, and 69–74 and peptide residues 208–210 are disordered,
consistent with chemical shifts close to random coil values and
the lack of medium- or long-range distance restraints between
residues in these regions. There are no consistent NOE violations
greater than 0.15 A˚ within the structured regions and >93% of
residues in these regions fall within the allowed or generously
allowed regions of the Ramachandran plot. Residues that fall
outside the standard secondary structure Ramachandran values
lie in the irregularly structuredN-loop, the b2-b3 turn or bordering
the disordered regions.
Description of the Structure
In the complex with Su1617 (Figure 3A), CCL11 adopts the ca-
nonical chemokine fold in which the only regular secondary
structure elements are a three-stranded antiparallel b sheet
(b1, residues 24–29; b2, 37–43; b3, 47–52) packed against a
C-terminal a helix (residues 56–68). As observed in other chemo-
kine structures, the first b strand is preceded by: the highly flex-
ible N terminus (residues 1–8); the CC motif (residues 9–10,
which form disulfide bonds to residues in the b1-b2 loop (30s
loop) and the b3-strand); an extended irregular structure known
as the N-loop (residues 11–19); and a single turn of 310-helix (the
310-turn, residues 20–23). The Su1617-bound structure of
CCL11 is very similar to that of free CCL11 (Crump et al., 1998;
Figure 3C), the only notable differences being a small (2 A˚) shift
of the b2-b3 turn toward the peptide, presumably induced by
peptide interactions (vide infra), and a subtle change in the angle
of the a helix relative to the b sheet.
The backbone structure of the Su1617 peptide is well defined
for residues Phe-211 to Leu-223 (Figure 3B), but the three N-ter-
minal residues (residues 208–210) are disordered. Residues Ser-
215 to Asp-218 form a tight, nonstandard turn, enabling the side
chains of Tys-216 and Tys-217 to both point toward the chemo-
kine. A second, less well-defined turn encompasses residues
Tys-217 to Leu-222.
The peptide lies on the surface of CCL11 with the aromatic
side chains protruding into two distinct shallow grooves (Fig-
ure 3A). The two Tys side chains occupy a cleft defined by the
N-loop residues Ala-14 to Pro-19, 310-turn residue Arg-22, and
b2/b3-strand residues Thr-43 to Ile-49 (Figure 3D). The aromatic
rings of both Tys residues form hydrophobic contacts with each
other and with Ile-18, Pro-19, and Ile-49 at the base of the bind-
ing cleft. In addition, Tys-216 interacts with the extended side
chain of Arg-16, whereas Tyr-217 is in close contact with Leu-45.
Three basic protein side chains are positioned appropriately to
stabilize binding of the sulfotyrosine side chains. The z-amino ni-
trogen of Lys-47 is positioned 3.3 ± 1.3 A˚ from one of the sulfate
oxygen atoms of Tys-217 and 4.3 ± 1.2 A˚ from one of the sulfate
oxygen atoms of Tys-216, sufficiently close to form salt bridges
in 17 of the 20 structures in the ensemble (Jeffrey, 1997). The
guanidinium group of Arg-22 is positioned 5 A˚ above the plane
of the Tys-217 aromatic ring in most structures, suggesting the
possible formation of a cation-p interaction, albeit slightly offset
from an ideal p-stacked arrangement; this interaction is sup-
ported by NOEs between Arg-22 Hd1/Hd2 and Tys-217 aromatic
protons. Although the side chains of Su1617 residues Asp-218
and Asp-219 are disordered, they also have the potential to
form favorable electrostatic interactions with Arg-22. The side
chain guanidinium group of Arg-16 is positioned adjacent to81, November 4, 2014 ª2014 Elsevier Ltd All rights reserved 1573
Figure 2. Intermolecular and Intrapeptide NOEs for CCL11:Su1617
(A and B) F1(13C)-F2(1H) planes from the F3-filtered 13C-HSQC-NOESY spectrum of CCL11:Su1617; F3 chemical shift values correspond to (A) Tys-217 Hd/Hε
(black) and Phe-211 Hd (red) and (B) Tys-216 Hd (cyan) resonances.
(C) Schematic representation of NOEs between Su1617 and N-loop/310-turn and b2- b3 regions of CCL11; the peptide sequence is shown in bold type and
intermolecular NOEs are shown as thin (%4 NOEs) or thick dashed lines (R5 NOEs).
(D) Medium-range NOEs within Su1617; line thickness is proportional to the number of NOEs observed.
Structure
Receptor Sulfopeptide Bound to CC Chemokinethe Tys-216 aromatic ring so that rotation of the Tys aromatic
ring would result in a standard cation-p interaction; again this
interaction is supported by NOEs between Arg-16 Hb2/Hg1/Hg2
and Tys-216 aromatic protons. All three of these basic side
chains are more highly ordered in the CCL11:Su1617 structure
than in the structure of free CCL11 (Crump et al., 1998;
Figure 3C).
In addition to the sulfotyrosine interactions, the side chain of
Phe-211 interacts with a second shallow groove defined by the
side chains of N-loop residues Asn-12, Leu-13, and Asn-15 as
well as residue Lys-55 of CCL11 (Figure S2A), although this re-
gion of the structure is partially disordered and the interaction
may be transient. Finally, C-terminal peptide residue (Leu-223)
interacts with the exposed hydrophobic side chain of residue
Leu-45 at the apex of the CCL11 b2-b3 turn (Figure 2C;
Figure S2B).
Contributions of Basic Residues to Binding
To determine the importance of the observed interactions be-
tween Tys residues in Su1617 and positively charged residues
in CCL11, we mutated CCL11 residues Arg-16, Lys-17, Arg-
22, and Lys-47 individually to Ala and determined the affinity of
each mutant for Su1617 as well as the ability of each mutant to
activate CCR3 expressed on HEK293 cells. The K17A mutant
was unstable and aggregated gradually. Other mutants dis-
played decreased affinity for Su1617 (Figures 4A and 4C) and
decreased potency for CCR3 activation (Figures 4B and 4C). In
particular, the R16A mutant displayed the most substantial re-
ductions in both Su1617 affinity (6.5-fold) and potency (13.7-1574 Structure 22, 1571–1581, November 4, 2014 ª2014 Elsevier Ltdfold). These data, supported by the excellent correlation (r2 =
0.95) between Su1617 binding and functional potency, suggest
that the interactions observed in the structure stabilize the com-
plex and position the chemokine suitably for receptor activation.
DISCUSSION
The Two-Site Model for Chemokine Receptor
Interactions
According to the prevailing two-site model proposed by Crump
and colleagues (Crump et al., 1997), two distinct sites on the
chemokine interact with two distinct sites on the receptor. Initial
receptor binding involves interaction of the chemokineN-loop re-
gion (site 1) with the receptor N-terminal region. This is followed
by the chemokine N-terminal region (site 2) engaging a shallow
binding site presumed to be located among the receptor extra-
cellular loops and/or transmembrane helices, thus giving rise to
a receptor conformational change and intracellular signaling.
Although this simple model is broadly consistent with the current
body of structure-function data, it should be noted that the inter-
actions of the two sites might not act entirely independently and/
or that additional structural features of the chemokine and/or the
receptor could influence binding or signaling. We discuss our
data within the context of the two-site model.
Recognition of the Sulfated Receptor N Terminus by a
CC Chemokine
We report the structure of a CC chemokine bound to a receptor
fragment. The structure shows that the sulfotyrosine residues ofAll rights reserved
Table 2. Structural Statistics for CCL1:Su1617 Ensemble of 20
Structures
Rmsd from Ideal Geometry
Bonds (A˚) 0.004 ± 0.000
Angles () 0.55 ± 0.01
Impropers () 0.36 ± 0.01
Rmsd from Experimental Restraints
Distance (A˚) 0.019 ± 0.003
Hydrogen bond (A˚) 0.009 ± 0.005
Dihedral angles () 0.22 ± 0.06
NOE Violations per Structure
>0.3 A˚ 0.2
>0.2 A˚ 0.7
>0.15 A˚ 2.2
Dihedral Violations per Structure
>3 0
>2 0.1
>1 0.5
Hydrogen Bond Violations per Structure > 0.05 A˚ 0
XPLOR Energies (kcal/mol)
Overall 176.3 ± 37.3
Bond lengths 21.5 ± 1.6
Bond angles 123.5 ± 5.0
Impropers 14.2 ± 0.9
Van der Waals 0.0 ± 0.0
NOE 13.1 ± 3.6
Dihedral 0.2 ± 0.1
Hydrogen bond 0.1 ± 0.1
Ramachandran 348.8 ± 35.8
Ramachandran Analysis (all residues/residues 12-29, 37-68; %)
Most favored regions 54.9/71.6
Additional allowed regions 30.6/21.6
Generously allowed regions 9.6/5.6
Disallowed regions 4.9/1.3
Average Pairwise Rmsd1 (backbone/heavy atoms; A˚)
All residues 3.22/3.29
Residues 12–29, 37–68 (ordered protein) 0.46/1.06
Residues 211–223 0.96/1.86
Residues 216–223 0.58/1.48
The structures were analyzed using AQUA and PROCHECK-NMR (Las-
kowski et al., 1996).
Structure
Receptor Sulfopeptide Bound to CC Chemokinethe CCR3 N-terminal peptide bind to a crevice on the CCL11
surface defined by the N-loop and b2-b3 structural elements
(Figure 3). This is consistent with the proposed first step of the
two-site model but emphasizes the importance of the b2-b3
element in addition to the N-loop region identified as site 1 in
the original two-site model (Crump et al., 1997).
Posttranslational sulfation of tyrosine residues is a common
feature of many chemokine receptors, enhancing both their
binding to and activation by chemokine ligands (Ludeman and
Stone, 2014). Sulfation of CCR3 N-terminal peptides enhances
binding to CCL11 by up to 30-fold for a single sulfate andStructure 22, 1571–15100-fold for two sulfate groups (Simpson et al., 2009). Like
other chemokine receptors, CCR3 is likely to be heteroge-
neously sulfated. Nevertheless, inhibition of sulfation reduces re-
ceptor activity by a factor of400 (Figure 1), suggesting that one
or both N-terminal Tyr residues are sulfated in a high proportion
of receptor molecules. Considering that CCL11 contains 16
basic and only 5 acidic residues, nonspecific electrostatic
attraction may contribute to the preference of CCL11 for the
sulfated form of the receptor. However, the CCL11:Su1617
structure also reveals specific interactions of the Tys-216 and
Tys-217 sulfated groups with the positively charged side chain
groups of chemokine residues Arg-16 and Lys-47, respectively.
Moreover, our mutational data (Figure 4) show that the most sig-
nificant contribution to Su1617 affinity is from Arg-16, whose
side chain interacts directly with the aromatic ring of Tys-216
in the CCR3 peptide. This is consistent with our previous obser-
vation that sulfation of Tyr-216 induces greater affinity enhance-
ments (15- or 28-fold) than sulfation of Tys-217 (4- or 7-fold;
Stone et al., 2009). In summary, the structural, binding, and func-
tional data indicate that Tyr sulfation in the N-terminal region
of CCR3 enhances binding to and activation by CCL11 through
specific interactions of the receptor sulfate groups with posi-
tively charged residues lining the binding crevice on the
chemokine.
Implications for Receptor Recognition by Other CC
Chemokines
CCR3 has three principal endogenous agonists (CCL11/eotaxin-
1, CCL24/eotaxin-2, and CCL26/eotaxin-3) and several other
chemokines are also identified as endogenous agonists of
CCR3 (http://www.iuphar-db.org; Sharman et al., 2013). Using
NMR chemical shift perturbation, we found that the CCR3
N-terminal peptide Su1617 binds to the N-loop/b2-b3 region of
all three principal endogenous ligands, although the affinity for
CCL24 is substantially weaker than that for the other two chemo-
kines (Zhu et al., 2011). Figure 3E shows a sequence alignment of
the N-loop and b2-b3 regions of the endogenous agonists of
CCR3; CCR2 and CCR5 ligands are also shown (see below).
Residues observed as forming important interactions with
Su1617 in the CCL11:Su1617 complex determined here are
highly conserved among the nine CCR3 ligands and colored in
Figure 3E. Among the residues forming the hydrophobic base
of the sulfotyrosine binding pocket, Ile-18 is retained or conser-
vatively substituted by Leu in all nine ligands, Pro-19 is retained
in seven of the ligands but replaced by Ser in the other two,
Thr-43 is completely conserved, and Ile-49 is retained or conser-
vatively substituted by Val in eight of the ligands. The three addi-
tional residues that interact with Tys-217 (Arg-22, Leu-45 and
Lys-47) are also highly conserved. In all nine ligands, at least
two of these residues are basic and Lys-47, which forms a salt
bridge to the Tys-217 sulfate group, is Lys or Arg in eight of
the ligands and Gln in the other one (see below). Similarly, the
Tys-216 recognition residue Arg-16 is retained as Arg or conser-
vatively substituted by Lys in all but one CCR3 ligand. Based on
the very high sequence conservation among the CCR3 ligands,
we propose that the doubly sulfated form of the CCR3 N termi-
nus is likely to bind to all the cognate ligands of this receptor in
a similar manner to that observed here for the CCL11:Su1617
complex.81, November 4, 2014 ª2014 Elsevier Ltd All rights reserved 1575
Figure 3. Structure of the CCL11:Su1617 Complex
(A) Ribbon representation showing CCL11 (residues 12–68, gray) with conserved disulfide bonds (yellow sticks) and Su1617 (residues 211–223, cyan) with side
chain sticks for Tys-216 and Tys-217 (red), Phe-211 (orange) and Leu-223 (green).
(B) Backbone ribbon structure of CCL11-bound Su1617 (superimposed over residues 211–223), with side chain sticks shown for residues with NOEs to CCL11.
Colors are the same as in panel (a); residues 208–210 are dark blue.
(C) Left: ensemble backbone Ca traces of free CCL11 (PDB code 2EOT, magenta) and Su1617-boundCCL11 (gray) optimally superimposed on b strand residues.
Right: side chain ensembles of the three critical basic residues superimposed on backbone atoms, showing the increased ordering of these side chains in the
bound state.
(D) CCL11 surface and Su1617 ribbon representations with Tys residues shown as red sticks; the surfaces of hydrophobic recognition residues in the Tys binding
site are orange and those of the three critical basic residues are blue with side chain sticks also shown.
(E) Aligned sequences of cognate CC chemokine ligands for receptors CCR3, CCR2, and CCR5; residues are colored as in (D) and conserved Cys residues are
shaded yellow. Bars on the right indicate which chemokines are ligands for each receptor. CCL28 has been reported as a ligand of CCR3 (John et al., 2005), but is
excluded because it cannot be readily aligned with the other chemokines.
Structure
Receptor Sulfopeptide Bound to CC ChemokineNotwithstanding thehigh sequence conservation, the structure
suggests possible explanations for the differences in Su1617 af-
finity among the three principal CCR3 agonists. Whereas, both
CCL11 and CCL26 bind to Su1617 with Kd values of 1 mM,
CCL24 binds considerably more weakly (Kd 14 mM; Zhu et al.,
2011). Among the nine CCR3 ligands shown in Figure 3E,
CCL24 is the only onewithout a b-branched hydrophobic residue
at the position corresponding to Ile-49 of CCL11 (this residue is
replaced by Ser) and the only one without a basic residue at the
position corresponding to Lys-47 of CCL11, which is replaced
by Gln. Although Gln has the potential to form a hydrogen bond
with theTys-217 sulfate group, theequivalent residue is positively
charged in all other CCR3 chemokines, suggesting that a salt
bridge is more favorable. It appears likely that the replacement
of these two conserved residues in CCL24 gives rise to the lower
affinity of this chemokine for theN-terminal region of CCR3. Simi-
larly, differences between the recognition residues of CCL11,
CCL24, and CCL26 are consistent with the distinct selectivities
of these three chemokines among CCR3 peptides containing
different patterns of Tyr sulfation (Zhu et al., 2011).1576 Structure 22, 1571–1581, November 4, 2014 ª2014 Elsevier LtdPrevious NMR studies have shown that sulfotyrosine-contain-
ing N-terminal peptides derived from two other CC chemokine re-
ceptors, CCR2 and CCR5, also bind to the N-loop/b2-b3 regions
of cognate chemokines (Duma et al., 2007; Schnur et al., 2013;
Tan et al., 2013a). Moreover, the recognition residues in the
CCL11:Su1617 structure are also highly conserved in CC chemo-
kines that recognize CCR2 and CCR5 (Figure 3E), suggesting that
the interactions observed in the current structure are conserved
across the CC chemokine family. However, whereas the sulfotyr-
osine residues of human CCR3 are adjacent, human CCR2 con-
tains two potentially sulfated tyrosine residues separated by one
aminoacidandhumanCCR5containsup to four sulfotyrosine res-
idues spread across the N-terminal sequence (positions 3, 10, 14,
and 15). Moreover, the arrangement of tyrosine residues (and
possibly the sulfation state) in these receptors varies across spe-
cies. Thus, if the recognition residues are conserved, the structure
of the bound receptor N terminus would be expected to vary
among these receptors to accommodate similar interactions.
The importance of residues in the N-loop/b2-b3 regions of CC
chemokines is further supported by studies of the viral CCAll rights reserved
Figure 4. Mutation of Basic Residues of
CCL11 Affects Su1617 Binding and CCR3
Activation
(A) NMR-derived curves for binding of Su1617 to
wild-type (WT) or mutant CCL11 (R16A, R22A, and
K47A). Data are normalized amide proton chemical
shift perturbations for the residue showing the
largest chemical shift change for each protein (A46
for WT, R16A, and R22A; K17 for K47A); solid lines
represent global fits obtained using shift data for
8–19 residues for each protein in a single titration
experiment.
(B) CCR3-mediated ERK1/2 phosphorylation upon
stimulation with WT or mutant CCL11 (R16A,
R22A, and K47A). Concentration-response curves
were generated in Flag-CCR3 FlpIn TRex HEK293 cells after 2.5 min stimulation with the corresponding ligands. Data points represent the mean ± SEM of
at least three independent experiments.
(C) NMR-derived Kd value (top) and half-maximal effective concentration (EC50) values for ERK1/2 phosphorylation (bottom); *p < 0.05, ***p < 0.005, one-way
ANOVA, Bonferroni posttest.
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Receptor Sulfopeptide Bound to CC Chemokinechemokine inhibitor (vCCI), which binds tightly to numerous
CC chemokines, thereby inhibiting their receptor interactions.
Recent biochemical and structural studies have shown that
vCCI interacts with a surface of CC chemokines that substan-
tially overlaps the region shown here to interact with the receptor
N terminus and that the same positively charged residues of the
chemokines contribute to stabilization of the vCCI interactions
(Beck et al., 2001; Kuo et al., 2014; Seet et al., 2001; Zhang
et al., 2006).
In addition to the recognition residues highlighted above, the
N-loops of CC chemokines contain two highly conserved hydro-
phobic (usually aromatic) residues, corresponding to Phe-11 and
Leu-13 of CCL11. Previous studies have shown that the residue
corresponding to Leu-13 contributes to the hydrophobic core (as
observed here) and is required for correct folding (Bondue et al.,
2002). However, the residue corresponding to Phe-11 plays a
critical role in receptor binding; nonconservative substitutions
cause substantial reductions in receptor affinity and potency,
suggesting that this residue contributes to site I binding interac-
tions (Hemmerich et al., 1999; Jarnagin et al., 1999; Laurence
et al., 2000; Mayer and Stone, 2001). In the current structure,
Phe-11 of CCL11 is disordered and does not interact with
the CCR3 sulfopeptide. Thus, it is possible that site I extends
beyond the interaction surface observed in the CCL11:Su1617
complex to include Phe-11 and interacting receptor residues.
We note, however, that the full N-terminal region of CCR3 and
the residue 8–23 peptide (corresponding to Su1617) bind to
CCL11 with similar affinities (Ye et al., 2000). Thus, we suggest
that the Phe-11 (or equivalent) residue may instead contribute
to subsequent interactions with other regions of the receptor
(site II). In this regard, it is noteworthy that chemokine binding
to intact receptors is much tighter than that to N-terminal
(sulfo)peptides, so affinities measured in cell-based binding as-
says contain contributions from both sites.
Comparison with Receptor Recognition by CXC
Chemokines
The CCL11:Su1617 structure has both similarities to and differ-
ences from the structures of dimeric CXC chemokines CXCL8
and CXCL12 bound to regions of their respective receptors,
CXCR1 and CXCR4 (Skelton et al., 1999; Veldkamp et al.,Structure 22, 1571–152008). Skelton and colleagues described the structure of a non-
covalent CXCL8 dimer bound to a peptidomimetic (CXCR1-p1)
containing two segments of the CXCR1 N-terminal region con-
nected by a hexanoic acid linker (Skelton et al., 1999). One of
these segments includes a Tyr residue that is likely to be sulfated
in the receptor (sequence DEDY) but is nonsulfated in CXCR1-
p1. The peptidomimetic interacts with a single chemokine proto-
mer, binds to the same face of the chemokine as observed for
Su1617 binding to CCL11, and utilizes residues corresponding
to Arg-16, Ile-18, Lys-47, and Ile-49 of CCL11 (Figure 5A;
Figure S3). However, the orientation of CXCR1-p1 on the
CXCL8 surface differs substantially from that observed in the
CCL11:Su1617 complex. Specifically, whereas the CCR3 sulfo-
peptide Su1617 lies approximately antiparallel to the b3 strand of
CCL11, the CXCR1-p1 peptidomimetic lies approximately
perpendicular to the b3 strand of CXCL8 (Figure 5A).
Veldkamp and colleagues reported structures of a cross-
linked CXCL12 dimer bound to residues 1–38 of CXCR4, either
nonsulfated, sulfated at Tyr-21, or sulfated at all three Tyr resi-
dues (Tyr-7, Tyr-12, and Tyr-21); the three complexes involve
similar interactions, with each peptide traversing the dimer
interface (Figure S3; Veldkamp et al., 2008). The binding site
for Tys-21 is the N-loop/b2-b3 cleft observed in the current
CCL11:Su1617 structure and the sulfate group of Tys-21 forms
a salt bridge with Arg-47, the equivalent residue to Lys-47 in
CCL11. However, the CXCR4 sulfopeptide peptidomimetic
lies approximately parallel to the b3 strand of CXCL12,
approximately 150 different from the orientation of the CCR3
sulfopeptide Su1617 in the complex with CCL11 (Figure 5A).
This substantial difference has profound implications for the
mechanism of receptor activation.
Implications for the Mechanism of Receptor Activation
The structures of the extracellular regions of chemokine recep-
tors are constrained by their attachment to the transmembrane
helices and by two conserved disulfide bonds: one from the N
terminus to ECL3 and the other between ECL1 and ECL2 (Fig-
ure 5C; Park et al., 2012; Tan et al., 2013b; Wu et al., 2010).
The conserved N-terminal Cys is located 7-8 residues before
the beginning of the first transmembrane helix (TM1) and the
intervening residues form an irregular loop (Figures 5B and 5C;81, November 4, 2014 ª2014 Elsevier Ltd All rights reserved 1577
Figure 5. Comparison of Receptor N Termi-
nus Binding by Chemokines
(A) Ribbon structures of (left) CCL11 bound to
CCR3 peptide Su1617, (center) CXCL8 bound to
CXCR1 peptidomimetic CXCR1-p1 (PDB code
1ILQ), and (right) CXCL12 bound to CXCR4 pep-
tide p38-sY3 (PDB code 2K05). The chemokines
are shown as gray ribbons with the conserved di-
sulfides as yellow sticks and the residue preceding
the CC/CXC motif in magenta (other N-terminal
residues are disordered and not shown); the
conserved basic residue corresponding to Lys-47
of CCL11 is shown as blue sticks. In each com-
plex, the receptor fragment is shown as a cyan
ribbonwith side chain sticks for Tys or Tyr residues
(red) and the residue preceding the conserved Cys
residue of the receptor (green). For the CXC che-
mokines, only one half of each dimeric complex
is shown. The structures were oriented by super-
imposition of the b sheet residues.
(B) Sequences of the N-terminal regions and first
transmembrane helices (TM1) of receptors CCR3,
CCR5, CXCR1, and CXCR4. Underlined residues
correspond to the N-terminal peptides used for
structure determination of chemokine complexes,
with residues colored as in (A). TM1 residues are
colored orange. The conserved N-terminal Cys
residues are shaded yellow.
(C) Structures of CCR5 (PDB code 4MBS), CXCR1
(PDB code 2LNL), and CXCR4 (PDB code 3ODU)
with each of the complexes from (A) rotated so that
the residues preceding the conserved N-terminal
Cys of the receptor (green sticks and cyan ribbons)
are oriented similarly relative to the receptor.
Receptor transmembrane segments are in pastel
tones (TM1, orange; TM2-3, purple; TM4-5, green;
TM6-7, pink) and the extracellular elements are
in saturated tones (N terminus, orange; ECL1, blue;
ECL2, green; ECL3, magenta). The conserved
disulfide bond between the N-terminal and ECL3
elements is shown as yellow sticks and the residue
preceding the N-terminal Cys is shown as green sticks and indicated by a green arrow. The chemokine-peptide complexes are colored as in (A) but the full
structural ensembles are shown for the chemokine N termini (magenta); the CXCL8:CXCR1-p1 structure contains only a single model for the N-terminal region.
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Receptor Sulfopeptide Bound to CC ChemokineFigure S4). However, in all three chemokine receptor structures
reported to date, the position of the N-terminal Cys residue is
conserved because it is disulfide bonded to the ECL3 Cys, which
is located at the N-terminal end of the TM7 helix (Figure 5C; Park
et al., 2012; Tan et al., 2013b; Wu et al., 2010).
In the solution structures of chemokines bound to N-terminal
receptor peptides, the receptor N-terminal Cys residues are
either not present or disordered (and mutated to Ala; Skelton
et al., 1999; Veldkamp et al., 2008). However, the residues imme-
diately preceding the receptor N-terminal Cys are present and
well defined. Due to the varying orientations of the receptor pep-
tides discussed above, these residues are bound to different
positions on the chemokine ligands (Figure 5A). Consequently,
if CCL11, CXCL8, and CXCL12 bind to their receptor N termini
in the samemanner as observed in their respective peptide com-
plexes, the three chemokines would assume distinct orientations
relative to the transmembrane helical bundles of their receptors,
allowing them to engage different regions of the receptors and
induce distinct conformational changes, as represented by the
models in Figure 5C. Notably, the orientation of CCL11 shown1578 Structure 22, 1571–1581, November 4, 2014 ª2014 Elsevier Ltdin Figure 5C is consistent with the data of Schnur and colleagues,
which suggested that the receptor ECL2 element interacts with
the opposite face of the chemokine from the receptor N terminus
(Schnur et al., 2013). At this stage, it would be speculative to
propose the details of the distinct interactions formed by
different chemokine:receptor pairs. Nevertheless, the current re-
sults and interpretation will allow more detailed modeling of the
overall chemokine-receptor complexes and subsequent testing
of receptor activation hypotheses.
Conclusions
We determined the structure of the monomeric CC chemokine
CCL11 bound to the sulfated N-terminal region of its receptor
CCR3. Comparison to the previous structures of dimeric CXC
chemokines bound to N-terminal fragments of their receptors
shows that these chemokines use a conserved site (site 1 of
the two-site model) and similar amino acid residues to recognize
markedly different receptor sequences. Consequently, after
binding at site 1, the relative orientations of the chemokines on
the receptors are predicted to differ substantially. We proposeAll rights reserved
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Receptor Sulfopeptide Bound to CC Chemokinethat these orientational differences influence the subsequent
engagement of the chemokines with other regions of the recep-
tor (site 2 interactions) and thereby have consequences for the
structure, stability, and signaling of the activated receptors.
EXPERIMENTAL PROCEDURES
Protein and Peptide Samples
Full-length human CCL11 (residues 1–74) was expressed in Escherichia coli as
an N-terminal His6-tagged fusion protein and purified (including tag removal
with thrombin to reveal the native N terminus) as previously described (Ye
et al., 2000). Uniformly 15N- and 15N,13C-labeled protein was expressed inmin-
imal media according to Staunton and colleagues (Staunton et al., 2009) and
confirmed by mass spectrometry. The peptide Su1617, comprising residues
8–23 of human CCR3 (sequence V8ETFGTTSY16Y17DDVGLL23) in which
both residues Y16 and Y17 are sulfated, was prepared using solid-phase syn-
thesis and purified by high-performance liquid chromatography as described
(Simpson et al., 2009; Zhu et al., 2011). CCL11mutant clones, some described
previously (Mayer and Stone, 2001), were prepared using the Quikchange
method (Stratagene) and expressed and purified similarly to wild-type protein.
Receptor Activation Assays
Cell-based assays were performed in inducible FlpIn TRex HEK293 cells ex-
pressing Flag-CCR3 under an inducible promoter, using methods described
previously for receptor CCR2 (Tan et al., 2012, 2013a). Activation of CCR3
by wild-type and mutant CCL11 was tested using an extracellular signal-regu-
lated kinase 1/2 (ERK1/2) phosphorylation assay. Briefly, cells were seeded at
50,000 cells/well into a poly-D-Lys-coated 96-well plate and grown overnight
in the presence of 1 mg/ml tetracycline. Concentration response experiments
were conducted by stimulating cells with agonist for 2.5 min. The reaction
was terminated by removal of media and drugs and addition of lysis buffer.
Samples were processed using the AlphaScreen SureFire pERK1/2 kit (Perkin
Elmer) and following manufacturer’s instructions. Data were normalized to the
response of fetal bovine serum and analyzed in GraphPad Prism 5.02. Inhibi-
tion of sulfation was achieved by growing the cells in media containing 30 mM
sodium chlorate for 48 hr prior to the experiment.
NMR Samples
CCL11 stock concentrations were determined by absorbance at 280 nm
(molar extinction coefficient = 8,730 l mol1 cm1). Su1617 stock concentra-
tions were estimated by reverse-phase high-performance liquid chromatog-
raphy (detection at 214 nm) with reference to an unsulfated version of the
same peptide with molar extinction coefficient 2,980 l mol1 cm1). NMR sam-
ples containing CCL11 and Su1617 in the molar ratio 1:1 (final concentrations
200–400 mM) in 20 mM deuterated sodium acetate, 0.02% NaN3, 5% D2O
(pH 6.5) were prepared by titrating peptide into protein (or vice versa) and
monitoring binding by NMR (15N-heteronuclear single-quantum coherence
[HSQC] spectra for protein; F2-filtered total correlation spectroscopy [TOCSY]
or 1H spectra for peptide) until saturation was reached.
NMR Assignments
Assignment and structure determination experiments were recorded on Varian
Inova or Bruker 600 MHz spectrometers equipped with triple-resonance cryo-
genic probes. 1H chemical shifts were referenced to DSS (0 ppm) and 13C and
15N were indirectly referenced to the DSS and ammonia, respectively (Wishart
et al., 1995). Assignments of 13C/15N-labeled CCL11 in the complex at 40C
were made using standard experiments (Sattler et al., 1999)—2D 15N-HSQC,
13C-HSQC, HB(CBCGCD)HD and HB(CBCGCDCE)HE; 3D 15N-TOCSY-
HSQC, 15N-NOESY-HSQC, 13C-NOESY-HSQC, HNCACB, CBCA(CO)NH,
HBHA(CO)NH, H(CCO)NH-TOCSY, (H)C(CO)NH-TOCSY, HC(C)H-TOCSY
and (H)CCH-TOCSY—supplemented by 3D HCAN and (HB)CBCA(CO)N(CA)
HA experiments (Kanelis et al., 2000) to aid assignment of proline-rich or
dynamic regions, in which NH resonances were not observable. 1H and 13C
TOCSYmixing timeswere 60ms and 11–16ms, respectively, whereas NOESY
mixing times were 120 ms. The valine and leucine isopropyl methyl groups
were stereospecifically assigned using a 13C-edited nonconstant time HSQC
collected on a 10% 13C-labeled sample in D2O (Neri et al., 1989) and HACAHBStructure 22, 1571–15and HNHB spectra allowed stereospecific assignment of 14 b-protons.
Assignments of unlabelled Su1617 at 25C were made using 2D TOCSY
(tmix = 80 ms) and ROESY (tmix = 300 ms) experiments and confirmed by
comparison to spectra of peptides with the same sequence but different Tyr
sulfation patterns. Assignments of unlabelled Su1617 at 40C were made by
comparison of 2D TOCSY spectra at 25C, 30C, 35C, and 40C. 2D assign-
ments of unlabelled Su1617 in the CCL11 complex at 40C were made by
comparison of F2-filtered TOCSY spectra of Su1617 containing increasing
concentrations of 15N,13C-CCL11 and were confirmed by analysis of u2-
filtered-TOCSY (tmix = 60 ms) and u2-filtered-NOESY (tmix = 120 ms) spectra.
Spectral analysis was performed using Sparky (T. D. Goddard and D. G.
Kneller, University of California, San Francisco). Backbone and side chain
assignments were 94% and 83% complete, respectively, for protein residues
1–6 and 11–73 (resonances for residues 7–10were not identified) and 74%and
90% complete, respectively, for all peptide residues (amide protons were not
identified for several residues).
Structure Determination
Structure calculations were performed by restrained torsion angle dynamics in
CYANA (Herrmann et al., 2002; version 2.1) and refined by restrained torsion
angle dynamics followed byCartesianminimization in XPLOR-NIH (Schwieters
et al., 2003; version 2.32). NOEs within CCL11 in the complex were obtained
from 15N- and 13C-edited NOESY-HSQC spectra. NOEs within Su1617
in the complex were obtained from the u2-filtered-NOESY spectrum and
intermolecular NOEs were obtained from 13C-edited NOESY-HSQC and u3-
filtered HSQC-NOESY spectra. NOE data were initially assigned using the
CANDID module of CYANA (Gu¨ntert, 2003, 2004). Subsequently, intrapeptide
and intermolecular NOEs were checked manually and additional NOE assign-
ments made iteratively following repeated rounds of structure calculations.
Backbone torsion angle constraints (294/c pairs) were calculated from protein
chemical shift assignments using the program TALOS (Shen et al., 2009). A
backbone NH to CO hydrogen bond restraint within the protein was added
in the later rounds of structure calculations if an unambiguous partner was pre-
sent in at least one-third of the initial structures inspected. The quality of the
structures was validated using AQUA and PROCHECK-NMR (Laskowski
et al., 1996) and PyMOL (version 1.3, Schro¨dinger) was used to inspect
structures.
Binding Affinity Measurements
The affinities of Su1617 binding to CCL11 were determined by NMR. 15N
HSQC spectra were recorded at 25C for samples of 15N-labeled CCL11
(wild-type and each mutant) alone and in the presence of 10, 20, 35, 50, 80,
and 150 mM Su1617 in 20 mM deuterated sodium acetate, 0.02% NaN3, 5%
D2O (pH 6.5). For each mutant, the weighted changes in chemical shift
(DdNH = jDdHj + 0.2jDdNj) were fit globally for several residues to a 1:1 binding
equation, as described (Simpson et al., 2009; Tan et al., 2013a; Zhu et al.,
2011).
ACCESSION NUMBERS
The PDB accession code for the structural ensemble reported in this paper is
2MPM. The BMRB accession number for the chemical shifts and structural
constraints reported in this paper is 19989.
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